See more : Ardent Health Partners, LLC (ARDT) Income Statement Analysis – Financial Results
Complete financial analysis of CNBX Pharmaceuticals Inc. (CNBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CNBX Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SOLXYZ Co., Ltd. (4284.T) Income Statement Analysis – Financial Results
- FS Bancorp (FXLG) Income Statement Analysis – Financial Results
- Pengdu Agriculture & Animal Husbandry Co.,Ltd. (002505.SZ) Income Statement Analysis – Financial Results
- World Fitness Services Ltd. (2762.TW) Income Statement Analysis – Financial Results
- Grupo Traxión, S.A.B. de C.V. (TRAXIONA.MX) Income Statement Analysis – Financial Results
CNBX Pharmaceuticals Inc. (CNBX)
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.07K | 410.17K | 29.96K | 0.00 | 7.16K | 9.84K | 9.60K | 5.68K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 198.53K | 220.93K | 0.00 | 0.00 | 1.00 | 7.02K | 0.00 | 0.00 | 0.00 | 58.11K | 1.65K | 144.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 130.07K | 410.17K | -168.57K | -220.93K | 7.16K | 9.84K | 9.60K | -1.34K | 112.50K | 0.00 | 0.00 | -58.11K | -1.65K | -144.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | -562.68% | 0.00% | 100.00% | 100.00% | 99.99% | -23.49% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 194.79K | 431.57K | 1.18M | 1.77M | 1.68M | 1.54M | 1.00M | 246.94K | 177.61K | 139.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 105.23K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 518.43K | 894.00K | 1.75M | 808.40K | 1.31M | 1.48M | 2.39M | 1.33M | 214.61K | 327.25K | 210.65K | 57.93K | 19.89K | 21.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 15.98K | 15.98K | 20.25K | 60.00K | 288.16K | 422.02K | 287.46K | 960.00 | 62.72K | 0.00 | 0.00 | 495.00 | 2.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 518.43K | 909.98K | 1.77M | 828.64K | 1.37M | 1.77M | 2.81M | 1.61M | 215.57K | 389.96K | 210.65K | 57.93K | 20.39K | 23.43K | 27.43K | 9.69K | 12.46K | 21.27K | 19.19K | 1.74K |
| Other Expenses | -1.00 | 0.00 | -722.24K | -706.86K | -4.36M | 19.62K | -4.00 | 2.00 | -3.00 | 7.10K | 4.51K | 0.00 | 20.39K | 125.66K | 27.43K | 4.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Operating Expenses | 713.21K | 1.34M | 2.95M | 2.60M | 3.05M | 3.31M | 3.82M | 1.86M | 393.18K | 536.50K | 215.16K | 57.93K | 20.39K | 125.66K | 27.43K | 114.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Cost & Expenses | 713.21K | 1.34M | 2.95M | 2.60M | 3.05M | 3.31M | 3.82M | 1.86M | 393.18K | 536.50K | 215.16K | 57.93K | 20.39K | 125.66K | 27.43K | 114.92K | 13.56K | 23.20K | -20.02K | 1.80K |
| Interest Income | 0.00 | 0.00 | 1.27K | 2.39K | 8.13K | 4.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 19.61K | 1.17K | 1.27K | 2.39K | 8.13K | 18.35K | 852.00 | 4.37K | 27.18K | 3.03K | 971.00 | 179.00 | 13.00 | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 72.32K | 162.06K | 198.53K | 220.93K | 215.16K | 188.93K | 88.44K | 7.02K | 1.58K | 1.30K | 86.00 | 179.00 | -37.49K | -214.22K | 167.48K | 0.00 | 1.08K | 1.08K | 0.00 | 0.00 |
| EBITDA | -603.27K | -3.55M | -3.52M | -3.15M | -7.24M | 1.34M | -3.72M | -1.92M | -278.42K | -540.09K | -218.09K | -56.22K | -21.55K | -165.73K | 56.31K | -114.92K | 1.41K | -21.27K | 20.02K | -1.80K |
| EBITDA Ratio | -463.79% | -864.77% | -11,608.52% | 0.00% | -101,317.54% | -31,444.24% | -39,083.42% | -32,492.59% | -248.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -583.14K | -931.38K | -2.95M | -2.60M | -3.04M | -3.30M | -3.81M | -1.85M | -280.68K | -539.53K | -216.13K | -58.11K | -1.65K | 144.41K | -111.17K | -114.92K | -27.46K | -23.20K | 20.02K | -1.80K |
| Operating Income Ratio | -448.31% | -227.07% | -9,860.37% | 0.00% | -42,524.12% | -33,563.01% | -39,670.12% | -32,616.08% | -249.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -112.06K | -2.78M | -769.28K | -594.27K | -4.42M | 4.44M | 32.11K | -79.94K | -26.50K | -1.86K | -3.01K | 1.53K | 36.99K | 55.73K | 1.17K | 4.92K | -16.44K | 3.20K | -40.02K | 0.00 |
| Income Before Tax | -695.20K | -3.71M | -3.72M | -3.19M | -7.47M | 1.13M | -3.78M | -1.93M | -307.18K | -541.39K | -219.14K | -56.40K | 17.10K | -110.00K | -110.00K | -110.00K | -30.00K | -20.00K | -20.00K | 0.00 |
| Income Before Tax Ratio | -534.46% | -904.57% | -12,428.23% | 0.00% | -104,337.88% | 11,510.41% | -39,335.66% | -34,022.54% | -273.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 45.77K | -704.47K | -4.35M | 37.97K | 32.96K | 4.37K | 27.18K | 3.03K | 50.86K | 0.00 | 18.75K | 195.87K | -79.93K | 4.92K | 13.90K | 3.20K | 21.00 | 1.80K |
| Net Income | -695.20K | -3.71M | -3.77M | -2.49M | -3.11M | 1.13M | -3.78M | -1.93M | -307.18K | -541.39K | -270.01K | -56.40K | -1.65K | -107.31K | -114.98K | -114.92K | -27.46K | -23.20K | -20.02K | -1.80K |
| Net Income Ratio | -534.46% | -904.57% | -12,581.02% | 0.00% | -43,490.25% | 11,510.41% | -39,335.66% | -34,022.54% | -273.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.42 | -3.08 | -2.16 | -2.78 | 1.03 | -3.76 | -2.10 | -0.36 | -0.65 | -0.32 | -4.98 | -0.15 | -9.47 | -10.14 | -10.14 | -2.42 | -2.05 | -2.40 | -0.86 |
| EPS Diluted | -0.02 | -0.42 | -3.08 | -2.16 | -2.78 | 1.03 | -3.76 | -2.10 | -0.36 | -0.65 | -0.32 | -4.98 | -0.15 | -9.47 | -10.14 | -10.14 | -2.42 | -2.05 | -2.40 | -0.86 |
| Weighted Avg Shares Out | 30.25M | 8.82M | 1.22M | 1.15M | 1.12M | 1.10M | 1.00M | 919.80K | 860.45K | 839.19K | 835.38K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 8.33K | 2.09K |
| Weighted Avg Shares Out (Dil) | 30.25M | 8.82M | 1.22M | 1.15M | 1.12M | 1.10M | 1.00M | 919.80K | 860.45K | 839.19K | 835.38K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 11.34K | 8.33K | 2.09K |
Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the interim results of its second in-vivo POC study evaluating the efficacy of company's...
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer,...
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
TEL AVIV, Israel and BETHESDA, Md., June 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Breast Cancer antitumor...
The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
TEL AVIV, Israel and BETHESDA, Md., May 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company's patent titled: "System and Method for High Throughput Screening of Cancer...
Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
TEL AVIV, Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had filed a patent application under the Patent Cooperation Treaty (PCT) for...
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy...
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study...
Source: https://incomestatements.info
Category: Stock Reports